WelChol® With Metformin in Treating Patients With Type 2 Diabetes
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
The purpose of the study is to see how safe and effective and tolerable the use of colesevelam hydrochloride is for type 2 diabetes when added to metformin alone or in combination with other anti-diabetic drugs.
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy and Safety of WelChol® in Type 2 Diabetics With Inadequate Glycemic Control on Metformin Monotherapy or Metformin Therapy in Combination With Other Oral Anti-Diabetic Agents
Study Start Date :
Actual Primary Completion Date :
Actual Study Completion Date :
Resource links provided by the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years to 75 Years (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Age 18-75 years, inclusive
Diagnosed with type 2 diabetes
Hemoglobin (HbA1c) between 7.5% to 9.5%
Prescribed an ADA accepted diet
Receiving stable dose of metformin alone or in combination with other oral anti-diabetic medications for 90 days before Visit 1
History of type 1 diabetes or ketoacidosis
History of chronic (more than 2 months) insulin therapy or the initiation of insulin for chronic treatment
History of pancreatitis
Recent severe cardiovascular disease
Allergy or toxic response to colesevelam or any of its components